Strand Therapeutics
- Founded: 2018
- Location: Boston, MA
- Employee range: 1 - 10
- Clinical stage: RD
- Therapy area: Solid tumors
- Drug types: ONC
- Lead product: Undisclosed
- Product link: https://www.strandtx.com/#about
- Funding: $45M A Nov 2022; $52M A Jun 2021; $6M seed Jun 2019
- Investors: FPV, Eli Lilly and Company, Potentum Partners, Playground Global
strandtx.com linkedin.com job board
Short description:
Gene Therapy
Drug notes:
Undisclosed RD hematological cancers
Long description:
Strand Therapeutics is developing mRNA therapeutics to treat cancer, heart diseases and rare diseases. mRNA has recently emerged as an effective, multi-functional and potentially curative treatment option for many patients. Strand’s approach to mRNA therapeutics is unique - creating mRNA constructs that contain information for self-replication and genetically programmed logic circuits. This application of synthetic biology to RNA therapeutics enables the creation of programmable, long-acting mRNA drugs such that the location, timing and intensity of expression can all be controlled. Stand has initially focused on treatment options for solid tumor cancers.
© 2023 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com